$26.39
0[0.00%]
At close: Apr 22
$26.39
0[0.00%]
PreMarket: 4:00PM EDT
4D Molecular Therapeutics
(NASDAQ:FDMT)4D Molecular Therapeutics Stock (NASDAQ:FDMT), Analyst Ratings, Price Targets, Predictions
4D Molecular Therapeutics Inc has a consensus price target of $40.55, established from looking at the 33 latest analyst ratings. The last 3 analyst ratings were released from RBC Capital, Barclays, and BMO Capital on April 15, 2024, April 15, 2024, and April 1, 2024. With an average price target of $49.33 between RBC Capital, Barclays, and BMO Capital, there's an implied 86.94% upside for 4D Molecular Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
Barclays
BMO Capital
Jefferies
HC Wainwright & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for 4D Molecular Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/15/2024 | FDMT | Buy Now | 4D Molecular Therapeutics | $26.39 | 51.57% | RBC Capital | Luca Issi | $35 → $40 | Maintains | Outperform | Get Alert |
| 04/15/2024 | FDMT | Buy Now | 4D Molecular Therapeutics | $26.39 | 70.52% | Barclays | Gena Wang | → $45 | Initiates | → Overweight | Get Alert |
| 04/01/2024 | FDMT | Buy Now | 4D Molecular Therapeutics | $26.39 | 138.73% | BMO Capital | Kostas Biliouris | $70 → $63 | Maintains | Outperform | Get Alert |
| 04/01/2024 | FDMT | Buy Now | 4D Molecular Therapeutics | $26.39 | 119.78% | Jefferies | Nalin Tejavibulya | $30 → $58 | Maintains | Buy | Get Alert |
| 03/01/2024 | FDMT | Buy Now | 4D Molecular Therapeutics | $26.39 | 36.42% | HC Wainwright & Co. | Matthew Caufield | → $36 | Reiterates | Buy → Buy | Get Alert |
| 02/07/2024 | FDMT | Buy Now | 4D Molecular Therapeutics | $26.39 | 206.93% | Goldman Sachs | Salveen Richter | → $81 | Reinstates | → Buy | Get Alert |
| 02/05/2024 | FDMT | Buy Now | 4D Molecular Therapeutics | $26.39 | 165.25% | BMO Capital | Kostas Biliouris | $50 → $70 | Maintains | Outperform | Get Alert |
| 02/05/2024 | FDMT | Buy Now | 4D Molecular Therapeutics | $26.39 | 32.63% | RBC Capital | Luca Issi | $25 → $35 | Maintains | Outperform | Get Alert |
| 01/29/2024 | FDMT | Buy Now | 4D Molecular Therapeutics | $26.39 | -5.27% | RBC Capital | Luca Issi | → $25 | Reiterates | Outperform → Outperform | Get Alert |
| 10/24/2023 | FDMT | Buy Now | 4D Molecular Therapeutics | $26.39 | 21.26% | Cantor Fitzgerald | Josh Schimmer | → $32 | Initiates | → Overweight | Get Alert |
| 08/11/2023 | FDMT | Buy Now | 4D Molecular Therapeutics | $26.39 | 17.47% | Chardan Capital | Geulah Livshits | → $31 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | FDMT | Buy Now | 4D Molecular Therapeutics | $26.39 | 36.42% | HC Wainwright & Co. | Matthew Caufield | → $36 | Reiterates | Buy → Buy | Get Alert |
| 07/31/2023 | FDMT | Buy Now | 4D Molecular Therapeutics | $26.39 | 36.42% | HC Wainwright & Co. | Matthew Caufield | → $36 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | FDMT | Buy Now | 4D Molecular Therapeutics | $26.39 | 17.47% | Chardan Capital | Geulah Livshits | $30 → $31 | Maintains | Buy | Get Alert |
| 07/05/2023 | FDMT | Buy Now | 4D Molecular Therapeutics | $26.39 | 13.68% | Chardan Capital | Geulah Livshits | → $30 | Initiates | → Buy | Get Alert |
| 06/08/2023 | FDMT | Buy Now | 4D Molecular Therapeutics | $26.39 | 25.05% | B of A Securities | Tazeen Ahmad | $28 → $33 | Maintains | Buy | Get Alert |
| 06/08/2023 | FDMT | Buy Now | 4D Molecular Therapeutics | $26.39 | 36.42% | HC Wainwright & Co. | Matthew Caufield | → $36 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | FDMT | Buy Now | 4D Molecular Therapeutics | $26.39 | 36.42% | HC Wainwright & Co. | Matthew Caufield | → $36 | Reiterates | Buy → Buy | Get Alert |
| 04/28/2023 | FDMT | Buy Now | 4D Molecular Therapeutics | $26.39 | 36.42% | HC Wainwright & Co. | Matthew Caufield | → $36 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for 4D Molecular Therapeutics (FDMT)?
The latest price target for 4D Molecular Therapeutics (NASDAQ: FDMT) was reported by RBC Capital on April 15, 2024. The analyst firm set a price target for $40.00 expecting FDMT to rise to within 12 months (a possible 51.57% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for 4D Molecular Therapeutics (FDMT)?
The latest analyst rating for 4D Molecular Therapeutics (NASDAQ: FDMT) was provided by RBC Capital, and 4D Molecular Therapeutics maintained their outperform rating.
When was the last upgrade for 4D Molecular Therapeutics (FDMT)?
The last upgrade for 4D Molecular Therapeutics Inc happened on November 15, 2022 when Goldman Sachs raised their price target to $68. Goldman Sachs previously had a neutral for 4D Molecular Therapeutics Inc.
When was the last downgrade for 4D Molecular Therapeutics (FDMT)?
The last downgrade for 4D Molecular Therapeutics Inc happened on August 12, 2022 when SVB Leerink changed their price target from $28 to $12 for 4D Molecular Therapeutics Inc.
When is the next analyst rating going to be posted or updated for 4D Molecular Therapeutics (FDMT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 4D Molecular Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 4D Molecular Therapeutics was filed on April 15, 2024 so you should expect the next rating to be made available sometime around April 15, 2025.
Is the Analyst Rating 4D Molecular Therapeutics (FDMT) correct?
While ratings are subjective and will change, the latest 4D Molecular Therapeutics (FDMT) rating was a maintained with a price target of $35.00 to $40.00. The current price 4D Molecular Therapeutics (FDMT) is trading at is $26.39, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.